HER2-positive Breast Cancer — Expanded Access Programs
Overview
Right2Hope maintains a directory of 33 expanded access programs, clinical trials, and compassionate use pathways listed for HER2-positive Breast Cancer. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with her2-positive breast cancer programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 29 programs are currently active or recruiting, with the remaining 4 in other lifecycle stages. Sponsors actively running programs in this area include Dana-Farber Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute, Hoffmann-La Roche, Memorial Sloan Kettering Cancer Center, QuantumLeap Healthcare Collaborative, and others.
By recruiting status
Snapshot of where every HER2-positive Breast Cancer program currently sits in its lifecycle.
- Active / Recruiting29
- Inactive4
Top sponsors
Organisations running the most HER2-positive Breast Cancer programs in the directory.
- Dana-Farber Cancer Institute5 programs
- H. Lee Moffitt Cancer Center and Research Institute3 programs
- Hoffmann-La Roche2 programs
- Memorial Sloan Kettering Cancer Center2 programs
- QuantumLeap Healthcare Collaborative2 programs
- Seagen, a wholly owned subsidiary of Pfizer2 programs
- Baylor Breast Care Center1 program
- City of Hope Medical Center1 program
- Filipa Lynce, MD1 program
- Fox Chase Cancer Center1 program
HER2-positive Breast Cancer programs (33)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Phase 1 Study of ZN-A-1041 for HER2-Positive Advanced Solid Tumors — Hoffmann-La Roche
- Phase 2 Study of Zanidatamab and Chemotherapy for HER2-positive Breast Cancer Before Surgery — Jazz Pharmaceuticals
- Phase II Study of Hormone Therapy, Pertuzumab, and Trastuzumab for Stage I Hormone Receptor-Positive, HER2-Positive Breast Cancer — Dana-Farber Cancer Institute
- Study on Surgery and Radiation Therapy for People with Breast Cancer — Memorial Sloan Kettering Cancer Center
- Study on Tucatinib or Placebo with Trastuzumab and Pertuzumab for Advanced HER2+ Breast Cancer — Seagen, a wholly owned subsidiary of Pfizer
- Study on Tucatinib vs. Placebo with T-DM1 for Advanced or Metastatic HER2+ Breast Cancer — Seagen, a wholly owned subsidiary of Pfizer
- An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic — Genentech, Inc.
- ATEMPT 2.0: Comparing Two Treatments After Surgery for HER2-Positive Breast Cancer — Dana-Farber Cancer Institute
- Study on Biomarker Optimization of Pre-Surgery Therapy in Breast Cancer — University of Illinois at Chicago
- Study on Atezolizumab with Paclitaxel, Trastuzumab, and Pertuzumab for Patients with Advanced HER-2 Positive Breast Cancer — Fox Chase Cancer Center
- Study on How Tumor Shrinkage Before Surgery Relates to Remaining Cancer in Early Breast Cancer Patients — Baylor Breast Care Center
- HERizon-Breast: Personalized Treatment Study for Long-Term Remission in HER2+ Metastatic Breast Cancer — Memorial Sloan Kettering Cancer Center
- I-SPY Trial: New and Personalized Treatments for Breast Cancer Before Surgery — QuantumLeap Healthcare Collaborative
- Margetuximab Access Program for Patients with HER2+ Breast Cancer — TerSera Therapeutics LLC
- Study on Margetuximab or Trastuzumab for Stage II-III HER2-Positive Breast Cancer — Dana-Farber Cancer Institute
- Study on Neoadjuvant HER2-Targeted Therapy and Immunotherapy with Pembrolizumab for HER2-Positive Breast Cancer — University of Texas Southwestern Medical Center
- PHESGO Maintenance After Initial T-DXd Treatment for HER2+ Advanced Breast Cancer — MedSIR
- PRE-ISPY Phase I/II Study for Advanced or High-Risk Cancers — QuantumLeap Healthcare Collaborative
- Study on Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab for HER2+ Breast Cancer Spread to the Brain and Spinal Fluid — H. Lee Moffitt Cancer Center and Research Institute
- Study Comparing RO7771950 and Tucatinib with Trastuzumab and Capecitabine for Advanced HER2-Positive Breast Cancer — Hoffmann-La Roche
- Study on Stereotactic Brain Radiation with or without AGuIX Gadolinium-Based Nanoparticles for Brain Metastases — Dana-Farber Cancer Institute
- Study on HER2 Directed Dendritic Cell Vaccine with Weekly Paclitaxel, Trastuzumab, and Pertuzumab — H. Lee Moffitt Cancer Center and Research Institute
- Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer — NRG Oncology
- Study on PC14586 for Patients with Advanced Solid Tumors with a TP53 Y220C Mutation (PYNNACLE) — PMV Pharmaceuticals, Inc
- The SAPPHO Study: Testing a New Treatment Plan for HER2+ Metastatic Breast Cancer — Dana-Farber Cancer Institute
- Study on Tucatinib with Capecitabine and Trastuzumab for Patients with Advanced HER2+ Breast Cancer — Seagen Inc.
- Trial of Pre-operative Neratinib and Hormone Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers — Ruth O'Regan
- Study on TDXD and Durvalumab for HER2 Positive or Low Inflammatory Breast Cancer — Filipa Lynce, MD
- Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer — H. Lee Moffitt Cancer Center and Research Institute
- Study on Anti-HER2 Therapy for Nigerian Women with HER2+ Breast Cancer Before and After Surgery — University of Chicago
- Study on Non-Surgical Treatment Approach for Managing Breast Cancer — Ohio State University Comprehensive Cancer Center
- Study on Pertuzumab, Trastuzumab, and Paclitaxel for Treating HER2-Positive Advanced Breast Cancer — City of Hope Medical Center
- Study on TVB-2640 and Trastuzumab with Paclitaxel or Hormone Therapy for Treating HER2 Positive Metastatic Breast Cancer — Mayo Clinic
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as HER2-positive Breast Cancer to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.